BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689-692. [PMID: 11003611 DOI: 10.1053/jhep.2000.17894] [Cited by in Crossref: 358] [Cited by in F6Publishing: 309] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Björkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002;277:5476-83. [PMID: 11739387 DOI: 10.1074/jbc.M108514200] [Cited by in Crossref: 59] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
2 Albright ES, Bell DSH. The Liver, Liver Disease, and Diabetes Mellitus: . The Endocrinologist 2003;13:58-66. [DOI: 10.1097/00019616-200301000-00011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 57.9] [Reference Citation Analysis]
4 Lirussi F, Mastropasqua E, Orando S, Orlando R, Lirussi F. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. The Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005165] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3-23. [PMID: 15757802 DOI: 10.1016/j.bpg.2004.10.004] [Cited by in Crossref: 214] [Cited by in F6Publishing: 198] [Article Influence: 13.4] [Reference Citation Analysis]
6 Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. [PMID: 26666336 DOI: 10.1186/s12876-015-0407-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
7 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
8 Baffy G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol 2013;1:131-7. [PMID: 26355775 DOI: 10.14218/JCTH.2013.00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
9 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 17.7] [Reference Citation Analysis]
10 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, Kudo M. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84 Suppl 1:43-49. [PMID: 22156485 DOI: 10.1159/000333212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
11 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 18.5] [Reference Citation Analysis]
12 Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2010;53:927-933. [PMID: 20739079 DOI: 10.1016/j.jhep.2010.05.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
13 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD005165. [PMID: 17253543 DOI: 10.1002/14651858.CD005165.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
14 Lunati ME, Grancini V, Agnelli F, Gatti S, Masserini B, Zimbalatti D, Pugliese G, Rossi G, Donato MF, Colombo M. Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. Dig Liver Dis. 2013;45:833-839. [PMID: 23816695 DOI: 10.1016/j.dld.2013.03.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
15 Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, Monden M. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology. 2007;243:422-430. [PMID: 17356175 DOI: 10.1148/radiol.2432051244] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
16 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
17 Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5. [PMID: 12085359 DOI: 10.1053/jhep.2002.33713] [Cited by in Crossref: 224] [Cited by in F6Publishing: 197] [Article Influence: 11.8] [Reference Citation Analysis]
18 Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006;12:523-534. [PMID: 16555318 DOI: 10.1002/lt.20738] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
19 Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14(30): 4771-4775 [PMID: 18720537 DOI: 10.3748/wjg.14.4771] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
20 Anagnostopoulos GK, Arvanitidis D, Tsiakos S, Margantinis G, Grigoriadis K, Kostopoulos P. Is Hepatocellular Carcinoma Part of the Natural History of Nonalcoholic Steatohepatitis?: . Journal of Clinical Gastroenterology 2003;37:88-9. [DOI: 10.1097/00004836-200307000-00025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
21 Hui J. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7. [DOI: 10.1053/jhep.2003.50320] [Cited by in Crossref: 301] [Cited by in F6Publishing: 267] [Article Influence: 16.7] [Reference Citation Analysis]
22 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 146] [Article Influence: 8.8] [Reference Citation Analysis]
23 Hsieh PH, Huang JY, Nfor ON, Lung CC, Ho CC, Liaw YP. Association of type 2 diabetes with liver cirrhosis: a nationwide cohort study. Oncotarget 2017;8:81321-8. [PMID: 29113391 DOI: 10.18632/oncotarget.18466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1239-1244. [PMID: 20505515 DOI: 10.1097/meg.0b013e32833aa19b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:1028-33.e2. [PMID: 22610002 DOI: 10.1016/j.cgh.2012.05.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
26 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 96] [Article Influence: 12.5] [Reference Citation Analysis]
27 George J, Liddle C. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. Mol Pharmaceutics 2008;5:49-59. [DOI: 10.1021/mp700110z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
28 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826. [PMID: 15382171 DOI: 10.1002/hep.20410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 128] [Article Influence: 2.6] [Reference Citation Analysis]
29 Saxena NK, Saliba G, Floyd JJ, Anania FA. Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 2003;89:311-20. [PMID: 12704794 DOI: 10.1002/jcb.10494] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 3.4] [Reference Citation Analysis]
30 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
31 Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004;444:3-12. [PMID: 14685853 DOI: 10.1007/s00428-003-0943-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 3.9] [Reference Citation Analysis]
32 Mccullough AJ. Update on Nonalcoholic Fatty Liver Disease: . Journal of Clinical Gastroenterology 2002;34:255-62. [DOI: 10.1097/00004836-200203000-00013] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
33 Lee H, Chung WC, Lee KM, Paik CN, Kim JH, Jeon HS, Jun KH, Chin HM. [A case of gastric adenocarcinoma presenting as portal hypertension]. Korean J Gastroenterol 2012;60:42-6. [PMID: 22832799 DOI: 10.4166/kjg.2012.60.1.42] [Reference Citation Analysis]
34 Aranda-Michel J. Nutrition in hepatic failure and liver transplantation. Curr Gastroenterol Rep. 2001;3:362-370. [PMID: 11470007 DOI: 10.1007/s11894-001-0061-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
35 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37:610-628.e4. [PMID: 25659911 DOI: 10.1016/j.clinthera.2014.12.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
37 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
38 Kim MJ, Park CH, Kim DH, Park MH, Park KC, Hyun MK, Lee AK, Moon HR, Chung HY. Hepatoprotective Effects of MHY3200 on High-Fat, Diet-Induced, Non-Alcoholic Fatty Liver Disease in Rats. Molecules 2018;23:E2057. [PMID: 30115876 DOI: 10.3390/molecules23082057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 van Werven J, Schreuder T, Nederveen A, Lavini C, Jansen P, Stoker J. Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. European Journal of Radiology 2010;75:e102-7. [DOI: 10.1016/j.ejrad.2009.12.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
40 Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087-2107. [PMID: 19475696 DOI: 10.1002/hep.20066] [Cited by in Crossref: 274] [Cited by in F6Publishing: 206] [Article Influence: 22.8] [Reference Citation Analysis]
41 Lefkowitch JH. Pathology of the liver. Curr Opin Gastroenterol 2001;17:197-204. [PMID: 17031160 DOI: 10.1097/00001574-200105000-00002] [Reference Citation Analysis]
42 Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD004996. [PMID: 17253535 DOI: 10.1002/14651858.CD004996.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 1.4] [Reference Citation Analysis]
43 Koneru B, Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation. 2002;73:325-330. [PMID: 11884924 DOI: 10.1097/00007890-200202150-00001] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 4.4] [Reference Citation Analysis]
44 Kuniholm MH, Lesi OA, Mendy M, Akano AO, Sam O, Hall AJ, Whittle H, Bah E, Goedert JJ, Hainaut P, Kirk GD. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008;116:1553-7. [PMID: 19057710 DOI: 10.1289/ehp.11661] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
45 Leite AB, Mattos AA, Mattos AZ, Coral GP, Evaldt S. Risk factors for nonalcoholic steatohepatitis in cryptogenic cirrhosis. Arq Gastroenterol 2012;49:245-9. [PMID: 23329217 DOI: 10.1590/s0004-28032012000400003] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191-2207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 217] [Cited by in F6Publishing: 208] [Article Influence: 15.5] [Reference Citation Analysis]
48 Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 273] [Article Influence: 20.9] [Reference Citation Analysis]
49 Gomez-dominguez E, Gisbert JP, Moreno-monteagudo JA, Garcia-buey L, Moreno-otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7. [DOI: 10.1111/j.1365-2036.2006.02926.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 9.2] [Reference Citation Analysis]
50 Yoo J, Lee S, Kim K, Yoo S, Sung E, Yim J. Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. Diabetes Res Clin Pract 2008;81:321-6. [PMID: 18571268 DOI: 10.1016/j.diabres.2008.05.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
51 Barritt AS 4th, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2011;45:372-378. [PMID: 20733515 DOI: 10.1097/mcg.0b013e3181eeaff0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
52 Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020;115:867-875. [PMID: 32149781 DOI: 10.14309/ajg.0000000000000588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
53 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States: NAFLD May Be a Common Underlying Liver Disease in Patients With Hepatocellular Carcinoma in the United States. Hepatology 2002;36:1349-54. [DOI: 10.1002/hep.1840360609] [Cited by in Crossref: 255] [Cited by in F6Publishing: 123] [Article Influence: 18.2] [Reference Citation Analysis]
54 Caldwell SH, Lee VD, Kleiner DE, Al-osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology 2009;8:346-52. [DOI: 10.1016/s1665-2681(19)31748-x] [Cited by in Crossref: 81] [Article Influence: 6.8] [Reference Citation Analysis]
55 Islam SMT, Won J, Khan M, Chavin KD, Singh I. Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis. Ann Hepatol 2020;19:466-71. [PMID: 31870746 DOI: 10.1016/j.aohep.2019.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Solga SF, Alkhuraishe A, Cope K, Tabesh A, Clark JM, Torbenson M, Schwartz P, Magnuson T, Diehl AM, Risby TH. Breath biomarkers and non-alcoholic fatty liver disease: Preliminary observations. Biomarkers. 2006;11:174-183. [PMID: 16766393 DOI: 10.1080/13547500500421070] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
57 Lin TY, Yeh ML, Huang CF, Huang CI, Dai CY, Hsieh MH, Chen SC, Huang JF, Yu ML, Chuang WL. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. Eur J Gastroenterol Hepatol 2019;31:224-9. [PMID: 30308578 DOI: 10.1097/MEG.0000000000001285] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363-373. [PMID: 11303298 DOI: 10.1053/jlts.2001.23011] [Cited by in Crossref: 281] [Cited by in F6Publishing: 232] [Article Influence: 14.1] [Reference Citation Analysis]
59 Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clinics in Liver Disease 2004;8:619-38. [DOI: 10.1016/j.cld.2004.04.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
60 Sanyal AJ;  American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725. [PMID: 12404245 DOI: 10.1053/gast.2002.36572] [Cited by in Crossref: 701] [Cited by in F6Publishing: 659] [Article Influence: 36.9] [Reference Citation Analysis]
61 Oo YH, Neuberger J. Recurrence of Nonviral Diseases. Clinics in Liver Disease 2007;11:377-95. [DOI: 10.1016/j.cld.2007.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014; 20(39): 14172-14184 [PMID: 25339805 DOI: 10.3748/wjg.v20.i39.14172] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
63 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 314] [Article Influence: 20.6] [Reference Citation Analysis]
64 Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 2012;61:454-62. [PMID: 22228717 DOI: 10.2337/db11-0613] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
65 Bardella MT, Valenti L, Pagliari C, Peracchi M, Farè M, Fracanzani AL, Fargion S. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2004;36:333-336. [PMID: 15191202 DOI: 10.1016/j.dld.2004.01.012] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
66 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 117] [Article Influence: 11.4] [Reference Citation Analysis]
67 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 28.9] [Reference Citation Analysis]
68 Yokogawa K, Matsui-Yuasa I, Tamura A, Terada M, Kojima-Yuasa A. Inhibitory effects of Ecklonia cava extract on high glucose-induced hepatic stellate cell activation. Mar Drugs 2011;9:2793-808. [PMID: 22363250 DOI: 10.3390/md9122793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
69 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 7.3] [Reference Citation Analysis]
70 Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-24. [PMID: 31182766 DOI: 10.1038/s41416-019-0488-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
71 Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 224] [Article Influence: 20.6] [Reference Citation Analysis]
72 Reha JL, Lee S, Hofmann LJ. Prevalence and Predictors of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery: A Department of Defense Experience. The American Surgeon 2014;80:595-9. [DOI: 10.1177/000313481408000624] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
73 Wang Y, Lin S, Sheu WH, Liu P, Tung K. Obesity and diabetic hyperglycemia were associated with serum alanine aminotransferase activity in patients with hepatitis B infection. Metabolism 2010;59:486-91. [DOI: 10.1016/j.metabol.2009.07.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
74 Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F, Angelico F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005166.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
75 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Alshammari GM, Balakrishnan A, Chinnasamy T. Butein protects the nonalcoholic fatty liver through mitochondrial reactive oxygen species attenuation in rats. Biofactors 2018;44:289-98. [PMID: 29672963 DOI: 10.1002/biof.1428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
77 Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682-9. [DOI: 10.1002/hep.21103] [Cited by in Crossref: 345] [Cited by in F6Publishing: 308] [Article Influence: 23.0] [Reference Citation Analysis]
78 Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-588. [PMID: 11950797 DOI: 10.1136/gut.50.5.585] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 6.5] [Reference Citation Analysis]
79 Senanayake SM, Niriella MA, Weerasinghe SK, Kasturiratne A, de Alwis JP, de Silva AP, Dassanayake AS, de Silva HJ. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes. 2012;5:663. [PMID: 23198995 DOI: 10.1186/1756-0500-5-663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
80 Björnsson E, Angulo P. Non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2009;42:1023-30. [DOI: 10.1080/00365520701514529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
81 Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
82 Caldwell SH, Zaidman JS, Hespenheide EE. The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidem Drug Safe 2003;12:303-6. [DOI: 10.1002/pds.833] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
83 Toriguchi K, Hatano E, Tanabe K, Takemoto K, Nakamura K, Koyama Y, Seo S, Taura K, Uemoto S. Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency. J Gastroenterol Hepatol. 2014;29:1109-1118. [PMID: 24329600 DOI: 10.1111/jgh.12481] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
84 Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x] [Cited by in Crossref: 428] [Cited by in F6Publishing: 398] [Article Influence: 26.8] [Reference Citation Analysis]
85 Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG. Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin: . Clinical Pharmacokinetics 2011;50:253-65. [DOI: 10.2165/11584350-000000000-00000] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
86 Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66-75. [PMID: 22050199 DOI: 10.1111/j.1365-2036.2011.04912.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 167] [Article Influence: 18.6] [Reference Citation Analysis]
87 Kim MY, Baik SK. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease]. Korean J Hepatol 2008;14:1-3. [PMID: 18367852 DOI: 10.3350/kjhep.2008.14.1.1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
88 Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10:S69-S73. [PMID: 14762843 DOI: 10.1002/lt.20033] [Cited by in Crossref: 151] [Cited by in F6Publishing: 133] [Article Influence: 8.9] [Reference Citation Analysis]
89 Heidari K, Amiri M, Kariman H, Bassiri M, Alimohammadi H, Hatamabadi HR. Differentiation of exudate from transudate ascites based on the dipstick values of protein, glucose, and pH. The American Journal of Emergency Medicine 2013;31:779-82. [DOI: 10.1016/j.ajem.2013.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Reply to: “NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis”. Journal of Hepatology 2018;69:973-5. [DOI: 10.1016/j.jhep.2018.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242. [PMID: 12085369 DOI: 10.1053/jhep.2002.34734] [Cited by in Crossref: 406] [Cited by in F6Publishing: 368] [Article Influence: 21.4] [Reference Citation Analysis]
92 Montano-Loza AJ, Sultan A, Falanga D, Loss G, Mason AL. Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. Liver Int 2009;29:1543-51. [PMID: 19663932 DOI: 10.1111/j.1478-3231.2009.02095.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
93 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am. 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2004.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
94 Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421-3438. [PMID: 21647651 DOI: 10.1007/s10620-011-1769-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
95 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96-101. [PMID: 19098856 DOI: 10.1038/ajg.2008.34] [Cited by in Crossref: 274] [Cited by in F6Publishing: 221] [Article Influence: 22.8] [Reference Citation Analysis]
96 Halegoua-de Marzio D, Navarro VJ. Hepatotoxicity of Cardiovascular and Antidiabetic Drugs. Drug-Induced Liver Disease. Elsevier; 2013. pp. 519-40. [DOI: 10.1016/b978-0-12-387817-5.00029-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
97 Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011;2011:592404. [PMID: 21991518 DOI: 10.5402/2011/592404] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
98 Silva MA, Ataide Tda R, Oliveira SL, Sant'ana AE, Cabral Júnior CR, Balwani Mdo C, de Oliveira FG, Santos MC. [Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats]. Arq Bras Endocrinol Metabol 2008;52:1145-55. [PMID: 19082303 DOI: 10.1590/s0004-27302008000700011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Sutedja DS, Gow PJ, Hubscher SG, Elias E. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transplant Proc. 2004;36:2334-2337. [PMID: 15561241 DOI: http: //dx.doi.orq/10.1016/j.transproceed.2004.07.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C, Obermeier F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011;55:1391-1399. [PMID: 21703208 DOI: 10.1016/j.jhep.2011.02.035] [Cited by in Crossref: 149] [Cited by in F6Publishing: 149] [Article Influence: 14.9] [Reference Citation Analysis]
101 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
102 Chiappini F, Barrier A, Saffroy R, Domart MC, Dagues N, Azoulay D, Sebagh M, Franc B, Chevalier S, Debuire B. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab Invest. 2006;86:154-165. [PMID: 16344856 DOI: 10.1038/labinvest.3700374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
103 Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002;123:375-8. [DOI: 10.1053/gast.2002.34453] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
104 Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002;17 Suppl 3:S377-S384. [PMID: 12472967 DOI: 10.1046/j.1440-1746.17.s3.31.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 7.9] [Reference Citation Analysis]
105 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 116] [Article Influence: 13.2] [Reference Citation Analysis]
106 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1697] [Article Influence: 180.6] [Reference Citation Analysis]
107 Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc 2003;35:2977-80. [PMID: 14697954 DOI: 10.1016/j.transproceed.2003.10.059] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
108 Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923. [PMID: 12668987 DOI: 10.1053/jhep.2003.50161] [Cited by in Crossref: 1764] [Cited by in F6Publishing: 1641] [Article Influence: 98.0] [Reference Citation Analysis]
109 Pariente A. [Diagnosis and management of non alcoholic fatty liver disease]. Gastroenterol Clin Biol 2009;33:413-24. [PMID: 19375255 DOI: 10.1016/j.gcb.2009.02.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
111 Vorobioff JD, Contreras F, Tanno F, Hernández L, Bessone F, Colombato L, Adi J, Fassio E, Felgueres M, Fernández G, Gaite L, Gibelli D, Darrichon HG, Lafage M, Lombardo D, López S, Mateo A, Mendizábal M, Pecoraro J, Ruf A, Ruiz P, Severini J, Stieben T, Sixto M, Zárate F, Barraza SB, Sierra ID, Pacheco VR, Roblero JP, Rojas JO, González PR, Rodríguez DSM, Sierralta A, Manchego AU, Valdes E, Yaquich P, Wolff R, Valdivia FB, Gallegos RC, Galloso R, Marcelo JS, Montes P, Tenorio L, Veramendi I, Alava E, Armijos X, Benalcazar G, Carrera E, Pazmiño GF, Díaz EM, Garassini M, Marrero RP, Infante M, Suárez DP, Gutiérrez JC, Reyes CMV, Serrano YM, Hernández RH, Martínez OM, González TP, Andara MT, Hernández MS, Gerona S, García I, Tijera F, López EP, Torres K, Garzón M. A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Ann Hepatol 2020;19:396-403. [PMID: 32418749 DOI: 10.1016/j.aohep.2020.03.007] [Reference Citation Analysis]
112 Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002;35:497-499. [PMID: 11826428 DOI: 10.1053/jhep.2002.31551] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
113 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533, viii. [PMID: 15331061 DOI: 10.1016/j.cld.2004.04.004] [Cited by in Crossref: 349] [Cited by in F6Publishing: 327] [Article Influence: 20.5] [Reference Citation Analysis]
114 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 310] [Article Influence: 65.8] [Reference Citation Analysis]
115 Burt A. Steatosis and steatohepatitis. Current Diagnostic Pathology 2001;7:141-7. [DOI: 10.1054/cdip.2001.0062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
116 Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709. [PMID: 14500857 DOI: 10.1093/qjmed/hcg120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
117 Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125-1149, ix. [PMID: 17964913 DOI: 10.1016/j.mcna.2007.06.001] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.1] [Reference Citation Analysis]
118 Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597. [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020] [Cited by in Crossref: 318] [Cited by in F6Publishing: 298] [Article Influence: 18.7] [Reference Citation Analysis]
119 Mercado-Irizarry A, Torres EA. Cryptogenic cirrhosis: Current knowledge and future directions. Clin Liver Dis (Hoboken) 2016;7:69-72. [PMID: 31041033 DOI: 10.1002/cld.539] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
120 Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Practice & Research Clinical Gastroenterology 2002;16:691-707. [DOI: 10.1053/bega.2002.0326] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
121 Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. J Clin Gastroenterol 2017;51:160-6. [PMID: 27580477 DOI: 10.1097/MCG.0000000000000666] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
122 Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, Diehl AM, Magnuson TH. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 2005;1:6-11. [PMID: 16925194 DOI: 10.1016/j.soard.2004.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
123 Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, Katz M, Solomon G, Halpern Z, Gertler A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology. 2009;49:278-286. [PMID: 19065677 DOI: 10.1002/hep.22584] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
124 Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002;47:1107-10. [PMID: 12018908 DOI: 10.1023/a:1015002526879] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
125 Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 2002;16:733-747. [PMID: 12406442 DOI: 10.1053/bega.2002.0334] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
126 Russo MW. Current concepts in the evaluation of patients for liver transplantation. Expert Review of Gastroenterology & Hepatology 2014;1:307-20. [DOI: 10.1586/17474124.1.2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
128 Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017;62:2915-2922. [PMID: 28744836 DOI: 10.1007/s10620-017-4684-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 28.3] [Reference Citation Analysis]
129 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 28.5] [Reference Citation Analysis]
130 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD;  American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017-1044. [PMID: 19243014 DOI: 10.1002/hep.22742] [Cited by in Crossref: 1217] [Cited by in F6Publishing: 1041] [Article Influence: 101.4] [Reference Citation Analysis]
131 Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-410. [PMID: 11984526 DOI: 10.1053/gast.2002.32995] [Cited by in Crossref: 271] [Cited by in F6Publishing: 266] [Article Influence: 14.3] [Reference Citation Analysis]
132 Lang S, Martin A, Kasper P, Schramm C, Kütting F, Goeser T, Steffen HM, Demir M. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol 2020;55:222-7. [PMID: 31990240 DOI: 10.1080/00365521.2020.1718747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
133 Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med. 2009;26:1235-1241. [PMID: 20002475 DOI: 10.1111/j.1464-5491.2009.02839.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
134 Charlton MR. Roadmap for improving patient and graft survival in the next 10 years. Liver Transpl. 2016;22:71-78. [PMID: 27514705 DOI: 10.1002/lt.24602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
135 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
136 Cadranel JF, Jouannaud V, Loison S. [Improving insulin resistance: certain progress in the management of patients with non-alcoholic steatohepatitis...but the story continues]. Gastroenterol Clin Biol 2004;28:265-7. [PMID: 15094675 DOI: 10.1016/s0399-8320(04)94916-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, Fiorelli G, Fargion S. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis. 2003;35:172-178. [PMID: 12779071 DOI: 10.1016/s1590-8658(03)00025-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
138 Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun 2018;2:821-35. [PMID: 30027140 DOI: 10.1002/hep4.1193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
139 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013; 5(6): 311-322 [PMID: 23805355 DOI: 10.4254/wjh.v5.i6.311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
140 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 14.7] [Reference Citation Analysis]
141 Harrison SA, Neuschwander-tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in Liver Disease 2004;8:861-79. [DOI: 10.1016/j.cld.2004.06.008] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
142 Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012;18:29-37. [PMID: 21932374 DOI: 10.1002/lt.22435] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
143 Álamo JM, Bernal C, Barrera L, Marín LM, Suárez G, Serrano J, Gómez MA, Padillo FJ. Liver transplantation in patients with cryptogenic cirrhosis: long-term follow-up. Transplant Proc. 2011;43:2230-2232. [PMID: 21839241 DOI: 10.1016/j.transproceed.2011.05.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
144 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013;5:311-322. [PMID: 23805355 DOI: 10.4254/wjh.v.5.i6.311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016;36:317-24. [DOI: 10.1111/liv.13031] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 18.8] [Reference Citation Analysis]
146 Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335. [PMID: 16355018 DOI: 10.1097/00000441-200512000-00011] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 8.5] [Reference Citation Analysis]
147 Bergasa NV, Mehlman J, Bir K. Aerobic exercise: a potential therapeutic intervention for patients with liver disease. Medical Hypotheses 2004;62:935-41. [DOI: 10.1016/j.mehy.2003.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
148 Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191-207, x-xi. [PMID: 17544979 DOI: 10.1016/j.cld.2007.02.006] [Cited by in Crossref: 166] [Cited by in F6Publishing: 153] [Article Influence: 11.9] [Reference Citation Analysis]
149 Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial: METFORMIN IN NASH. Alimentary Pharmacology & Therapeutics 2004;20:23-8. [DOI: 10.1111/j.1365-2036.2004.02025.x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 226] [Article Influence: 14.9] [Reference Citation Analysis]
150 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578-584. [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013] [Cited by in Crossref: 187] [Cited by in F6Publishing: 161] [Article Influence: 11.0] [Reference Citation Analysis]
151 Mallory MA, Lee SW, Kowdley KV. Abnormal liver test results on routine screening: How to evaluate, when to refer for a biopsy. Postgraduate Medicine 2015;115:53-66. [DOI: 10.3810/pgm.2004.03.1461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1410] [Cited by in F6Publishing: 1314] [Article Influence: 78.3] [Reference Citation Analysis]
153 Rim MY, Kwon OS, Ha M, Kim JS, Ko KI, Kim DK, Jang PK, Han JY, Park PH, Jung YK, Choi DJ, Kim YS, Kim JH. [Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma]. Korean J Gastroenterol 2014;63:292-8. [PMID: 24870301 DOI: 10.4166/kjg.2014.63.5.292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
154 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
155 Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Ann Hepatol. 2017;16:188-197. [PMID: 28233739 DOI: 10.5604/16652681.1231562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
156 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
157 Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179-187. [PMID: 14752836 DOI: 10.1002/hep.20023] [Cited by in Crossref: 286] [Cited by in F6Publishing: 270] [Article Influence: 16.8] [Reference Citation Analysis]
158 Contos MJ, Choudhury J, Mills AS, Sanyal AJ. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:481-500, vii. [PMID: 15331059 DOI: 10.1016/j.cld.2004.04.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
159 Wells SA. Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America 2014;22:397-416. [DOI: 10.1016/j.mric.2014.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
160 Lefkowitch JH. Steatosis, Steatohepatitis and Related Conditions. Scheuer's Liver Biopsy Interpretation. Elsevier; 2010. pp. 93-114. [DOI: 10.1016/b978-0-7020-3410-7.00013-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
161 Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A; ACE Collaborating Group. Prevalence and etiology of altered liver tests: A population-based survey in a Mediterranean town. Hepatology 2005;41:1151-9. [DOI: 10.1002/hep.20689] [Cited by in Crossref: 118] [Cited by in F6Publishing: 111] [Article Influence: 7.4] [Reference Citation Analysis]
162 Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity. J Clin Diagn Res 2014;8:62-6. [PMID: 24596725 DOI: 10.7860/JCDR/2014/6691.3953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
163 Dooghaie Moghadam A, Eslami P, Razavi-Khorasani N, Moazzami B, Zahedi-Tajrishi F, Farokhi E, Makhdoomi Sharabiani K, Mansour-Ghanaei A, Mehrvar A, Aghajanpoor Pasha M, Saeedi S, Iravani S. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian J Intern Med 2020;11:346-54. [PMID: 33680375 DOI: 10.22088/cjim.11.4.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Lemoine M. Stéatopathie métabolique: définition et histoire naturelle. Gastroentérologie Clinique et Biologique 2009;33:398-404. [DOI: 10.1016/j.gcb.2009.02.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
166 Tardu A, Karagul S, Yagci MA, Ertugrul I, Sumer F, Kirmizi S, Yaylak F, Koc C, Hatipoglu S, Kayaalp C, Yilmaz S. Histopathological Examination of Explanted Liver After Transplantation in Patients With Cryptogenic Cirrhosis. Transplant Proc 2015;47:1450-2. [PMID: 26093740 DOI: 10.1016/j.transproceed.2015.04.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
167 Muhie OA. Causes and Clinical Profiles of Ascites at University of Gondar Hospital, Northwest Ethiopia: Institution-Based Cross-Sectional Study. Can J Gastroenterol Hepatol 2019;2019:5958032. [PMID: 31360695 DOI: 10.1155/2019/5958032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P. A Clinical–Morphological Study on Cholestatic Presentation of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2005;50:1130-5. [DOI: 10.1007/s10620-005-2719-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
169 Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol 2014;81:523-8. [DOI: 10.1111/cen.12369] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
170 Chen Z, Han CK, Pan LL, Zhang HJ, Ma ZM, Huang ZF, Chen S, Zhuang XJ, Li ZB, Li XY. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects. Dig Dis Sci. 2014;59:2470-2476. [PMID: 24861033 DOI: 10.1007/s10620-014-3214-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
171 Gambarin–gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh H, Futterweit W. Prevalence of Nonalcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome. Clinical Gastroenterology and Hepatology 2007;5:496-501. [DOI: 10.1016/j.cgh.2006.10.010] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 7.5] [Reference Citation Analysis]
172 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
173 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
174 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 23.4] [Reference Citation Analysis]
175 Lonardo A, Bagni A, Tarugi P, Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol. 2004;16:1043-1050. [PMID: 15371930 DOI: 10.1097/00042737-200410000-00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
176 Schult A, Mehlig K, Björkelund C, Wallerstedt S, Kaczynski J. Waist-to-hip ratio but not body mass index predicts liver cirrhosis in women. Scandinavian Journal of Gastroenterology 2018;53:212-7. [DOI: 10.1080/00365521.2017.1420219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
177 Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathol Int. 2006;56:40-45. [PMID: 16398679 DOI: 10.1111/j.1440-1827.2006.01916.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
178 Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, Tozzi G, Pujatti PL, Labbadia G, Corazza GR, Averna M, Perticone F, Croce G, Persico M, Bucci T, Baratta F, Polimeni L, Del Ben M, Violi F, Violi F, Angelico F, Pastori D, Baratta F, Del Ben M, Polimeni L, Labbadia G, Basili S, Raparelli V, Napoleone L, Corradini SG, Ferri F, Monica P, Mischitelli M, Lucia P, Tozzi G, D'amico J, Colzi M, Andreozzi P, Perticone F, Caroleo B, Corazza GR, Michela M, Gaetano B, Sacerdoti D, Brocco S, Angelico M, Santopaolo F, Francioso S, Pujatti PL, Faedo A, Andriulli A, Ippolito AM, Bolondi L, Tovoli F, Fargion S, Fracanzani AL, Davì G, Di Michele D, Croce G, Averna M, Giammanco A, Persico M, Bucci T, Iuliano L, Ciacciarelli M. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis 2017;262:179-84. [DOI: 10.1016/j.atherosclerosis.2017.03.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
179 Devries MC, Samjoo IA, Hamadeh MJ, Tarnopolsky MA. Effect of Endurance Exercise on Hepatic Lipid Content, Enzymes, and Adiposity in Men and Women. Obesity 2008;16:2281-8. [DOI: 10.1038/oby.2008.358] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 7.2] [Reference Citation Analysis]
180 Yu JH, Lee KS, Lee SY, Hong AR, Park YS. The association of cardiovascular risk factors with nonalcoholic fatty liver disease in health checkup examinees. J Prev Med Public Health. 2008;41:407-412. [PMID: 19037170 DOI: 10.3961/jpmph.2008.41.6.407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
181 Thuluvath PJ. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transpl 2005;11:S25-9. [DOI: 10.1002/lt.20606] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
182 Kim YS. [Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis in patients with portal hypertension]. Korean J Gastroenterol 2010;56:168-85. [PMID: 20847607 DOI: 10.4166/kjg.2010.56.3.168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
184 Sorom AJ, Nyberg SL, Gores GJ. Keratin, fas, and cryptogenic liver failure. Liver Transpl. 2002;8:1195-1197. [PMID: 12474161 DOI: 10.1053/jlts.2002.0081195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
185 Saadeh S. Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract. 2007;22:1-10. [PMID: 17242448 DOI: 10.1177/011542650702200101] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
186 Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name.... Journal of Hepatology 2018;68:391-2. [DOI: 10.1016/j.jhep.2017.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
187 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 76.0] [Reference Citation Analysis]
188 Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol. 2002;9:37-51. [PMID: 11756758 DOI: 10.1097/00125480-200201000-00005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
189 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 244] [Article Influence: 49.6] [Reference Citation Analysis]
190 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
191 Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation. 2002;74:1007-1012. [PMID: 12394846 DOI: 10.1097/00007890-200210150-00019] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
192 Takino JI, Nagamine K, Hori T, Sakasai-Sakai A, Takeuchi M. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2459-2469 [PMID: 26483867 DOI: 10.4254/wjh.v7.i23.2459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
193 Fraisse T, Savey L, Hentgen V, Rossi-Semerano L, Koné-Paut I, Grateau G, Georgin-Lavialle S, Ducharme-Bénard S. Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review. Liver Int 2020;40:1269-77. [PMID: 32196885 DOI: 10.1111/liv.14445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
194 Abdelmalek MF, Diehl AM. Mechanisms underlying nonalcoholic steatohepatitis. Drug Discovery Today: Disease Mechanisms 2006;3:479-88. [DOI: 10.1016/j.ddmec.2006.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
195 Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49:1578-1583. [PMID: 15573908 DOI: 10.1023/b:ddas.0000043367.69470.b7] [Cited by in Crossref: 144] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]
196 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
197 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 168] [Article Influence: 82.5] [Reference Citation Analysis]
198 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone A, Bagni A, Bertolotti M, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002;34:204-11. [DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
199 Sutedja DS, Gow PJ, Hubscher SG, Elias E. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transplant Proc. 2004;36:2334-2337. [PMID: 15561241 DOI: 10.1016/j.transproceed.2004.07.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
200 Corbin IR, Furth EE, Pickup S, Siegelman ES, Delikatny EJ. In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2009;1791:757-63. [DOI: 10.1016/j.bbalip.2009.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
201 Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6. [DOI: 10.1002/hep.1840400411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
202 Runyon BA;  AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087-2107. [PMID: 19475696 DOI: 10.1002/hep.22853] [Cited by in Crossref: 567] [Cited by in F6Publishing: 453] [Article Influence: 47.3] [Reference Citation Analysis]
203 Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199-206. [PMID: 20451282 DOI: 10.1016/j.jhep.2010.01.040] [Cited by in Crossref: 126] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
204 Satapathy SK, Nair S, Vanatta JM. Nonalcoholic fatty liver disease following liver transplantation. Hepatol Int 2013;7:400-12. [PMID: 26201774 DOI: 10.1007/s12072-013-9434-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
205 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021;12:843-861. [PMID: 33586120 DOI: 10.1007/s13300-021-01011-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
206 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
207 Kibrit J, Khan R, Jung BH, Koppe S. Clinical Assessment and Management of Portal Hypertension. Semin Intervent Radiol 2018;35:153-9. [PMID: 30087517 DOI: 10.1055/s-0038-1660793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
208 Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539] [Cited by in CrossRef: 165] [Cited by in F6Publishing: 140] [Article Influence: 23.6] [Reference Citation Analysis]
209 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
210 Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002;31:641-62. [PMID: 12134622 DOI: 10.1016/s0889-8553(02)00017-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
211 Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35:105-109. [PMID: 11786965 DOI: 10.1053/jhep.2002.30318] [Cited by in Crossref: 293] [Cited by in F6Publishing: 233] [Article Influence: 15.4] [Reference Citation Analysis]
212 Ma JL, He LL, Li P, Jiang Y, Hu JL, Zhou YL, Liang XX, Wei HS. Clinical Features and Outcomes of Repeated Endoscopic Therapy for Esophagogastric Variceal Hemorrhage in Cirrhotic Patients: Ten-Year Real-World Analysis. Gastroenterol Res Pract 2020;2020:5747563. [PMID: 32508912 DOI: 10.1155/2020/5747563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
213 Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97-103. [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 253] [Article Influence: 15.8] [Reference Citation Analysis]
214 Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 26.3] [Reference Citation Analysis]
215 Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev Gastroenterol Hepatol. 2008;2:59-79. [PMID: 19072371 DOI: 10.1586/17474124.2.1.59] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
216 Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(18): 2223-2226 [PMID: 20458758 DOI: 10.3748/wjg.v16.i18.2223] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
217 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84. [PMID: 28052624 DOI: 10.1111/liv.13299] [Cited by in Crossref: 312] [Cited by in F6Publishing: 277] [Article Influence: 78.0] [Reference Citation Analysis]
218 Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens. 2010;28:1699-1707. [PMID: 20467324 DOI: 10.1097/hjh.0b013e32833a7de6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
219 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, Tamagawa Y, Fukui H. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol 2006; 12(13): 2080-2085 [PMID: 16610061 DOI: 10.3748/wjg.v12.i13.2080] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
221 Marmur J, Bergquist A, Stål P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand J Gastroenterol 2010;45:60-9. [PMID: 20030578 DOI: 10.3109/00365520903384742] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
222 Rosmorduc O. Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments? Ann Endocrinol (Paris). 2013;74:115-120. [PMID: 23597944 DOI: 10.1016/j.ando.2013.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
223 Yang Y, Zhang XZ, Ng HS, Fong JC, Lee LH. The effect of chronic liver disease on venous thromboembolism among medically managed patients in Singapore General Hospital. Thromb Res 2015;136:548-51. [PMID: 26164397 DOI: 10.1016/j.thromres.2015.06.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
224 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 32.5] [Reference Citation Analysis]
225 Gitto S, Falcini M, Marra F; MEDITRA Research Group. Metabolic Disorders After Liver Transplantation. Metab Syndr Relat Disord 2021;19:65-9. [PMID: 33104408 DOI: 10.1089/met.2020.0068] [Reference Citation Analysis]
226 Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005;7:32-36. [PMID: 15701296 DOI: 10.1007/s11894-005-0063-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
227 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
228 Samara K, Liu C, Soldevila-Pico C, Nelson DR, Abdelmalek MF. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig Dis Sci. 2006;51:1226-1229. [PMID: 16944015 DOI: 10.1007/s10620-006-8038-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
229 Koehler E, Watt K, Charlton M. Fatty Liver and Liver Transplantation. Clinics in Liver Disease 2009;13:621-30. [DOI: 10.1016/j.cld.2009.07.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
230 Hübscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2004;16:1107-1115. [PMID: 15489567 DOI: 10.1097/00042737-200411000-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
231 Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678. [PMID: 12406438 DOI: 10.1053/bega.2002.0333] [Cited by in Crossref: 283] [Cited by in F6Publishing: 273] [Article Influence: 15.7] [Reference Citation Analysis]
232 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 825] [Article Influence: 79.2] [Reference Citation Analysis]
233 Caldwell S. Cryptogenic Cirrhosis: What Are We Missing? Curr Gastroenterol Rep 2010;12:40-8. [DOI: 10.1007/s11894-009-0082-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
234 Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002;16:703-716. [PMID: 12468416 DOI: 10.1053/beem.2002.0225] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.6] [Reference Citation Analysis]
235 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x. [PMID: 21689610 DOI: 10.1016/j.cld.2011.03.006] [Cited by in Crossref: 286] [Cited by in F6Publishing: 288] [Article Influence: 28.6] [Reference Citation Analysis]
236 Watt KD. Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 2011;17 Suppl 3:S38-S42. [PMID: 21761552 DOI: 10.1002/lt.22386] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
237 Liew ZH, Goh GB, Hao Y, Chang PE, Tan CK. Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades. Dig Dis Sci 2019;64:585-90. [PMID: 30327962 DOI: 10.1007/s10620-018-5331-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
238 Vida Perez L, Montero Alvarez JL, Poyato Gonzalez A, Briceño Delgado J, Costan Rodero G, Fraga Rivas E, Barrera Baena P, De la Mata Garcia M. Prevalence and Predictors of Metabolic Syndrome After Liver Transplantation. Transplant Proc 2016;48:2519-24. [PMID: 27742339 DOI: 10.1016/j.transproceed.2016.08.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
239 Hussain HK, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, Appelman HD, Adusumilli S, Greenson JK, Conjeevaram HS. Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology. 2005;237:1048-1055. [PMID: 16237138 DOI: 10.1148/radiol.2373041639] [Cited by in Crossref: 221] [Cited by in F6Publishing: 197] [Article Influence: 13.8] [Reference Citation Analysis]
240 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
241 Mohammed OK, Mahadeva S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study. J Gastroenterol Hepatol. 2015;30:1423-1428. [PMID: 25867030 DOI: 10.1111/jgh.12978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
242 Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967-974. [PMID: 19107341 DOI: 10.1007/s00535-008-2264-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
243 Wlazlo N, Beijers HJBH, Schoon EJ, Sauerwein HP, Stehouwer CDA, Bravenboer B. High prevalence of diabetes mellitus in patients with liver cirrhosis: Diabetes in liver cirrhosis. Diabetic Medicine 2010;27:1308-11. [DOI: 10.1111/j.1464-5491.2010.03093.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
244 Rodríguez-Hernández H, Gonzalez JL, Rodríguez-Morán M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res 2005;36:362-6. [PMID: 15950075 DOI: 10.1016/j.arcmed.2005.03.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
245 Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122:274-280. [PMID: 11832442 DOI: 10.1053/gast.2002.31065] [Cited by in Crossref: 209] [Cited by in F6Publishing: 200] [Article Influence: 11.0] [Reference Citation Analysis]
246 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012;36:202-8. [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
247 Scott CH, Cha KM, Ngai J, Jiang C, Cheng K, Stokes RA, Ho KWK, George J, Gonzalez FJ, Gunton JE. Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PLoS One 2017;12:e0186543. [PMID: 29190746 DOI: 10.1371/journal.pone.0186543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
248 Zamin JI, de Mattos AA, Perin C, Ramos GZ. [The importance of AST / ALT rate in nonalcoholic steatohepatitis diagnosis]. Arq Gastroenterol 2002;39:22-6. [PMID: 12184161 DOI: 10.1590/s0004-28032002000100005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
249 Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64-71. [PMID: 15690483 DOI: 10.1002/hep.20543] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 8.3] [Reference Citation Analysis]
250 Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485-3493. [PMID: 25042049 DOI: 10.1002/cncr.28832] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
251 Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223-231. [PMID: 21476917 DOI: 10.1586/egh.11.8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
252 Alswat KA, Mumtaz K, Jafri W. Liver biopsy for histological assessment: The case in favor. Saudi J Gastroenterol 2010;16:133-9. [PMID: 20339188 DOI: 10.4103/1319-3767.61245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
253 Gaya DR, McLay AL, Oien KA, Spooner RJ, Reilly TG. A tale of two sisters. J Clin Pathol 2004;57:439-41. [PMID: 15047754 DOI: 10.1136/jcp.2003.012013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
254 Jawairia M, Subhani M, Siddiqui G, Prasad A, Shahzad G, Rizvon K, Mustacchia P. Unexplained findings of kayser-fleischer-like rings in a patient with cryptogenic cirrhosis. Case Rep Gastrointest Med 2012;2012:438525. [PMID: 22606437 DOI: 10.1155/2012/438525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
255 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. [DOI: 10.1053/gast.2002.34168] [Cited by in Crossref: 998] [Cited by in F6Publishing: 935] [Article Influence: 52.5] [Reference Citation Analysis]
256 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
257 Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011; 17(36): 4055-4062 [PMID: 22039318 DOI: 10.3748/wjg.v17.i36.4055] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
258 Castelló B, Aguilera V, Blázquez MT, Rubín Á, García M, Vinaixa C, Benlloch S, Sanjuan F, Montalva E, López R, Berenguer M. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. Annals of Hepatology 2019;18:855-61. [DOI: 10.1016/j.aohep.2019.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
259 Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-tainturier M, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93. [DOI: 10.1053/jhep.2002.33324] [Cited by in Crossref: 329] [Cited by in F6Publishing: 302] [Article Influence: 18.3] [Reference Citation Analysis]
260 Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Malé PJ, Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology. 2001;39:119-124. [PMID: 11493327 DOI: 10.1046/j.1365-2559.2001.01208.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 4.0] [Reference Citation Analysis]
261 Thuluvath PJ, Hanish S, Savva Y. Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. Transplantation 2018;102:656-63. [DOI: 10.1097/tp.0000000000002030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
262 Shi SY, Luk CT, Schroer SA, Kim MJ, Dodington DW, Sivasubramaniyam T, Lin L, Cai EP, Lu SY, Wagner KU, Bazinet RP, Woo M. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. J Biol Chem 2017;292:3789-99. [PMID: 28100771 DOI: 10.1074/jbc.M116.752519] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
263 Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PMID: 21248661 DOI: 10.1097/tp.0b013e31820b6b84] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
264 Møhlenberg M, Terczynska-dyla E, Thomsen KL, George J, Eslam M, Grønbæk H, Hartmann R. The role of IFN in the development of NAFLD and NASH. Cytokine 2019;124:154519. [DOI: 10.1016/j.cyto.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
265 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 505] [Article Influence: 59.6] [Reference Citation Analysis]
266 Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851-859. [PMID: 19115377 DOI: 10.1002/hep.22734] [Cited by in Crossref: 377] [Cited by in F6Publishing: 341] [Article Influence: 31.4] [Reference Citation Analysis]
267 Gasparin FRS, Carreño FO, Mewes JM, Gilglioni EH, Pagadigorria CLS, Natali MRM, Utsunomiya KS, Constantin RP, Ouchida AT, Curti C, Gaemers IC, Elferink RPJO, Constantin J, Ishii-iwamoto EL. Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:2495-509. [DOI: 10.1016/j.bbadis.2018.04.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
268 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
269 Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002;16:767-781. [PMID: 12406444 DOI: 10.1053/bega.2002.0329] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
270 Scott C, Stokes R, Cha KM, Clouston A, Eslam M, Metwally M, Swarbrick MM, George J, Gunton JE. Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PLoS One. 2019;14:e0225332. [PMID: 31800592 DOI: 10.1371/journal.pone.0225332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-752. [PMID: 11915019 DOI: 10.1053/jhep.2002.32483] [Cited by in Crossref: 174] [Cited by in F6Publishing: 163] [Article Influence: 9.2] [Reference Citation Analysis]
272 Kim J, Kim S, Lee W, Cheon Y, Lee S, Ju A, K M, Kim D. The Effects of Alcohol Abstinence on BDNF, Ghrelin, and Leptin Secretions in Alcohol-Dependent Patients with Glucose Intolerance. Alcohol Clin Exp Res 2013;37:E52-8. [DOI: 10.1111/j.1530-0277.2012.01921.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
273 Moreno-Sánchez D. [Epidemiology and natural history of primary nonalcoholic fatty liver disease]. Gastroenterol Hepatol 2006;29:244-54. [PMID: 16584696 DOI: 10.1157/13085972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
274 Zhang KY, Tung BY, Kowdley KV. Liver Transplantation for Metabolic Liver Diseases. Clinics in Liver Disease 2007;11:265-81. [DOI: 10.1016/j.cld.2007.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
275 El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, Moonka D, Huang MA, Brown K. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant. 2012;26:E505-E512. [PMID: 23061759 DOI: 10.1111/ctr.12014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
276 Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 2006;7:627-633. [PMID: 16845716 DOI: 10.1631/jzus.2006.b0627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
277 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 14.1] [Reference Citation Analysis]
278 Kremer M, Hines IN, Milton RJ, Wheeler MD. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology. 2006;44:216-227. [PMID: 16799967 DOI: 10.1002/hep.21221] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
279 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468. [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065] [Cited by in Crossref: 788] [Cited by in F6Publishing: 687] [Article Influence: 46.4] [Reference Citation Analysis]
280 Cortez-pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Practice & Research Clinical Gastroenterology 2004;18:1089-104. [DOI: 10.1016/j.bpg.2004.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
281 Ratziu V, Imbert-Bismut F, Messous D, Poynard T. The elusiveness of "normal" ALT in fatty liver. Hepatology 2004;39:1172; author reply 1173. [PMID: 15057921 DOI: 10.1002/hep.20187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
282 Jain D, Nayak NC, Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol. 2012;24:840-848. [PMID: 22495397 DOI: 10.1097/meg.0b013e3283534b40] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
283 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
284 Clemente Ricote G, García Monzón C. Estado actual de la esteatohepatitis no alcohólica. Medicina Clínica 2003;121:102-8. [DOI: 10.1016/s0025-7753(03)73870-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
285 Kallwitz ER. Metabolic syndrome after liver transplantation: Preventable illness or common consequence? World J Gastroenterol 2012; 18(28): 3627-3634 [PMID: 22851856 DOI: 10.3748/wjg.v18.i28.3627] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
286 Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Hematology/Oncology Clinics of North America 2003;17:625-46. [DOI: 10.1016/s0889-8588(03)00018-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
287 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 203] [Article Influence: 27.9] [Reference Citation Analysis]
288 Amarapurkar A, Ghansar T. Fatty liver: Experience from western India. Annals of Hepatology 2007;6:37-40. [DOI: 10.1016/s1665-2681(19)31951-9] [Cited by in Crossref: 14] [Article Influence: 1.0] [Reference Citation Analysis]
289 Dikdan GS, Saba SC, dela Torre AN, Roth J, Wang S, Koneru B. Role of oxidative stress in the increased activation of signal transducers and activators of transcription-3 in the fatty livers of obese Zucker rats. Surgery 2004;136:677-85. [DOI: 10.1016/j.surg.2004.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
290 García-Bañuelos J, Panduro A, Gordillo-Bastidas D, Gordillo-Bastidas E, Muñoz-Valle JF, Gurrola-Díaz CM, Sánchez-Enríquez S, Ruiz-Madrigal B, Bastidas-Ramírez BE. Genetic polymorphisms of genes coding to alcohol-metabolizing enzymes in western Mexicans: association of CYP2E1*c2/CYP2E1*5B allele with cirrhosis and liver function. Alcohol Clin Exp Res 2012;36:425-31. [PMID: 21895718 DOI: 10.1111/j.1530-0277.2011.01617.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
291 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
292 Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005;82:1046-51. [PMID: 16280437 DOI: 10.1093/ajcn/82.5.1046] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 8.0] [Reference Citation Analysis]
293 Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. Ann Diagn Pathol 2018;37:83-90. [PMID: 30312882 DOI: 10.1016/j.anndiagpath.2018.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
294 Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014;61:S69-78. [DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 13.6] [Reference Citation Analysis]
295 Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11(38): 5944-5950 [PMID: 16273604 DOI: 10.3748/wjg.v11.i38.5944] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
296 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
297 Shih L, Liou T, Chao JC, Kau H, Wu Y, Shieh M, Yeh C, Han B. Leptin, Superoxide Dismutase, and Weight Loss: Initial Leptin Predicts Weight Loss*. Obesity 2006;14:2184-92. [DOI: 10.1038/oby.2006.256] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
298 Bhat M, Usmani SE, Azhie A, Woo M. Metabolic Consequences of Solid Organ Transplantation. Endocr Rev 2021;42:171-97. [PMID: 33247713 DOI: 10.1210/endrev/bnaa030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Song HR, Yun KE, Park HS. Relation between alanine aminotransferase concentrations and visceral fat accumulation among nondiabetic overweight Korean women. Am J Clin Nutr 2008;88:16-21. [PMID: 18614719 DOI: 10.1093/ajcn/88.1.16] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
300 Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406-412. [PMID: 14960525 DOI: 10.1136/gut.2003.018770] [Cited by in Crossref: 194] [Cited by in F6Publishing: 187] [Article Influence: 11.4] [Reference Citation Analysis]
301 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
302 Charlton MR. Improving Long-Term Outcomes After Liver Transplantation. Clinics in Liver Disease 2014;18:717-30. [DOI: 10.1016/j.cld.2014.05.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
303 Jang BK. Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients? Clin Mol Hepatol 2016;22:336-8. [PMID: 27729635 DOI: 10.3350/cmh.2016.0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
304 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 2017; 23(8): 1458-1468 [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
305 Koh WP, Dan YY, Goh GB, Jin A, Wang R, Yuan JM. Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study. Liver Int 2016;36:893-901. [PMID: 26443688 DOI: 10.1111/liv.12978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
306 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 107.6] [Reference Citation Analysis]
307 Mathur SK, Jain P, Mathur P. Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications. J Obes 2011;2011:587495. [PMID: 21603273 DOI: 10.1155/2011/587495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
308 Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16(29): 3603-3615 [PMID: 20677332 DOI: 10.3748/wjg.v16.i29.3603] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 97] [Article Influence: 9.7] [Reference Citation Analysis]
309 Washburn ER, Yang Z. Interpretation of core biopsy of liver mass lesions: A comparison study between cytopathologist and gastrointestinal pathologist. Annals of Diagnostic Pathology 2019;40:152-60. [DOI: 10.1016/j.anndiagpath.2019.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]